For its third fiscal quarter (ending September 30), Celldex Therapeutics Inc (NASDAQ: CLDX) has reported E.P.S. of $-0.81 compared to $-0.57 a year ago. This performance was $-0.15 short of the consensus estimate of $-0.66. E.P.S. were $-2.64 for the latest four quarters through September 30 versus $-2.26 for the same period a year ago.
Recent Price Action
On 11/2/23, Celldex Therapeutics Inc (NASDAQ: CLDX) stock increased 1.9%, closing at $24.01. Relative to the market the stock has been weak over the last nine months but has risen 2.2% during the last week.
Current PriceTarget Research Rating
CLDX is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Celldex Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Celldex Therapeutics has a very low Power Rating of 15 and a very low Appreciation Score of 4, producing the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment